Stockscreener 앱 받기
32.58
2.24%
0.68
전일 마감가:
$31.90
열려 있는:
$31.65
하루 거래량:
1.66M
Relative Volume:
0.73
시가총액:
$3.13B
수익:
$47.30M
순이익/손실:
$-225.97M
주가수익비율:
-13.86
EPS:
-2.35
순현금흐름:
$-188.86M
1주 성능:
-15.70%
1개월 성능:
-3.13%
6개월 성능:
+7.93%
1년 성능:
+14.28%
1일 변동 폭
$31.64
$33.68
1주일 범위
$29.00
$41.47
52주 변동 폭
$22.71
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
명칭
Scholar Rock Holding Corp
전화
857-259-3860
주소
301 BINNEY STREET, CAMBRIDGE, MA
SRRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
32.58 | 3.07B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.47 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
474.44 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.02 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
816.94 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.70 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 개시 | BofA Securities | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 개시 | Leerink Partners | Outperform |
| 2025-08-21 | 재개 | Jefferies | Buy |
| 2025-07-30 | 재개 | Raymond James | Strong Buy |
| 2025-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-26 | 재확인 | H.C. Wainwright | Buy |
| 2024-10-07 | 재확인 | H.C. Wainwright | Buy |
| 2024-03-28 | 개시 | Raymond James | Strong Buy |
| 2023-10-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-04-03 | 재개 | Piper Sandler | Overweight |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-07-12 | 개시 | Truist | Buy |
| 2022-03-23 | 개시 | H.C. Wainwright | Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-03-12 | 개시 | Robert W. Baird | Outperform |
모두보기
Scholar Rock Holding Corp 주식(SRRK)의 최신 뉴스
Candlestick signals on Scholar Rock Holding Corporation stock todayDividend Hike & Stepwise Swing Trade Plans - newser.com
Scholar Rock stock falls as FDA issues OAI for Catalent site - Investing.com Nigeria
Why Is Scholar Rock Stock Trading Lower On Monday? - Sahm
FDA issues official action indicated status for Catalent Indiana facility owned by Novo Nordisk - Investing.com UK
FDA issues official action indicated status for Catalent Indiana facility owned by Novo Nordisk By Investing.com - Investing.com South Africa
Scholar Rock (SRRK) Valuation in Focus as Analyst Initiation and Insider Buying Signal Renewed Optimism - simplywall.st
Scholar Rock (SRRK) Faces Regulatory Challenges Impacting Stock - GuruFocus
Why Scholar Rock Stock Got Socked on Monday - The Motley Fool
Scholar Rock (SRRK) Sees Significant Stock Decline - GuruFocus
Scholar Rock (NASDAQ:SRRK) Shares Gap DownWhat's Next? - MarketBeat
Scholar Rock Sees Unusually Large Options Volume (NASDAQ:SRRK) - MarketBeat
Scholar Rock (SRRK) Shares Plummet Amid Market Volatility - GuruFocus
Scholar Rock says FDA determined Catalent Indiana inspection classification as OAI - MarketScreener
Scholar Rock Says FDA Determined Catalent Indiana Inspection Classification As OAI - TradingView
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Multi factor analysis applied to Scholar Rock Holding Corporation - newser.com
Why Scholar Rock Stock Raced 6% Higher Today - AOL.com
Why analysts remain bullish on Scholar Rock Holding Corporation stockTake Profit & Fast Entry High Yield Tips - newser.com
Is Scholar Rock Holding Corporation a good long term investmentGap Fill Strategies & Exceptional Profit Trading - earlytimes.in
A Key Insider Purchase At Scholar RockInsider Weekends (NASDAQ:SRRK) - Seeking Alpha
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Purchases 455,753 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Will Analyst Attention on SRRK Spotlight the Strategic Risks in Scholar Rock’s FDA Response Plan? - simplywall.st
Scholar Rock Holding's Srinivas Akkaraju Acquires 3,707% More Stock - Yahoo Finance
Scholar Rock jumps following Regeneron Eylea update - MSN
Bank of America Begins Coverage on Scholar Rock (NASDAQ:SRRK) - MarketBeat
What MACD and RSI say about Scholar Rock Holding CorporationTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
Why Scholar Rock (SRRK) Stock is Gaining Today - GuruFocus
BofA Securities initiates coverage on Scholar Rock stock with Buy rating - Investing.com Nigeria
This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B of A Securities Initiates Coverage on SRRK with a Buy Rating | - GuruFocus
Why Scholar Rock Holding Corporation (2QK) stock stays on top picksJuly 2025 Catalysts & Smart Investment Allocation Insights - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Scholar Rock (NASDAQ:SRRK) - MarketBeat
Visualizing Scholar Rock Holding Corporation stock with heatmapsJuly 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer - Reuters
Insider Stock Purchases: October 08, 2025 - Quiver Quantitative
Scholar Rock Holding Corporation Stock (SRRK) Opinions on Insider Purchase and FDA Delay - Quiver Quantitative
Wednesday’s Insider Activity: Top Buys and Sells from Tuesday Trading By Investing.com - Investing.com Nigeria
Srinivas Akkaraju Acquires 113,025 Shares of Scholar Rock (NASDAQ:SRRK) Stock - MarketBeat
Scholar Rock (NASDAQ:SRRK) Director Purchases $14,438,919.78 in Stock - MarketBeat
Scholar Rock (SRRK) director Akkaraju buys shares worth $18.8 million - Investing.com
Scholar Rock Holding Corporation (SRRK) Stock Analysis: Navigating a 20% Potential Upside in Biotech - DirectorsTalk Interviews
A Fresh Look at Scholar Rock (SRRK) Valuation Following FDA Setback for Apitegromab Approval - simplywall.st
Scholar Rock (SRRK): Assessing Valuation Following FDA Setback for Apitegromab Approval - Yahoo Finance
How strong is Scholar Rock Holding Corporation (2QK) stock earnings growth2025 Year in Review & Fast Exit and Entry Strategy Plans - newser.com
Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years - Sahm
Historical volatility pattern of Scholar Rock Holding Corporation visualizedMarket Risk Report & Reliable Volume Spike Alerts - newser.com
Will Scholar Rock Holding Corporation (2QK) stock recover faster than industryWeekly Trade Review & High Conviction Buy Zone Alerts - newser.com
Published on: 2025-10-05 01:03:01 - newser.com
Will Scholar Rock Holding Corporation (2QK) stock sustain uptrend momentum - newser.com
Scholar Rock Surges 405% in 2024 Is There Still Upside After Recent Pipeline Progress? - simplywall.st
Published on: 2025-10-03 06:20:05 - newser.com
Scholar Rock Holding Corp (SRRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.10%
0.05%
자본화:
|
볼륨(24시간):